Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study (Neurology and Therapy, (2023), 12, 6, (1937-1958), 10.1007/s40120-023-00533-1)

In the sentences beginning ‘At baseline,…’ and ‘The reduction of early morning…’ in the section ‘Efficacy’ under the heading ‘Results’ in this article, the n/N values ‘129/238, 20/139, 25/125 and 56/125’ were incorrect and the correct sentences should have read as follows: At baseline, 77.7% (n/N = 129/166) of patients experienced morning akinesia, which decreased to 19.2% (n/N = 20/104) at week 26, and 27.8% (n/N = 25/90) at week 52. The reduction of early morning “Off” time was accompanied by a marked increase in the proportion of patients reporting “On” time without dyskinesia on awakening (62.2%; n/N = 56/90 at week 52) (Fig. 3). In the sentence beginning ‘The reduction of “Off” time is particularly exemplified by…’ under the heading “Discussion”, the value ‘(changed from 17.5% at baseline to 63.0% at week 52)’ should have read ‘(changed from 17.5% at baseline to 62.2% at week 52).’ The original article has been corrected.